Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.

CAS  PubMed  Google Scholar 

Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–5.

PubMed  Google Scholar 

Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.

CAS  PubMed  Google Scholar 

Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90–01 randomized trial. J Clin Oncol. 1999;17(8):2396.

CAS  PubMed  Google Scholar 

Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34(31):3773–80.

PubMed  Google Scholar 

Artinyan A, Orcutt ST, Anaya DA, Richardson P, Chen GJ, Berger DH. Infectious postoperative complications decrease long-term survival in patients undergoing curative surgery for colorectal cancer: a study of 12,075 patients. Ann Surg. 2015;261(3):497–505.

PubMed  Google Scholar 

Matsuda A, Maruyama H, Akagi S, Inoue T, Uemura K, Kobayashi M, et al. Do postoperative infectious complications really affect long-term survival in colorectal cancer surgery? A multicenter retrospective cohort study. Ann Gastroenterol Surg. 2023;7(1):110–20.

PubMed  Google Scholar 

Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011;253(5):890–9.

PubMed  Google Scholar 

Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5 yrear follow-up of the RAPIDO trial. Ann Surg. 2023;278(4):e766–72.

PubMed  Google Scholar 

Sylla P, Rattner DW, Delgado S, Lacy AM. NOTES transanal rectal cancer resection using transanal endoscopic microsurgery and laparoscopic assistance. Surg Endosc. 2010;24(5):1205–10.

PubMed  Google Scholar 

van Oostendorp SE, Belgers HJ, Bootsma BT, Hol JC, Belt E, Bleeker W, et al. Locoregional recurrences after transanal total mesorectal excision of rectal cancer during implementation. Br J Surg. 2020;107(9):1211–20.

PubMed  Google Scholar 

Wasmuth HH, Faerden AE, Myklebust T, Pfeffer F, Norderval S, Riis R, et al. Transanal total mesorectal excision for rectal cancer has been suspended in Norway. Br J Surg. 2020;107(1):121–30.

CAS  PubMed  Google Scholar 

Caycedo-Marulanda A, Lee L, Chadi SA, Verschoor CP, Crosina J, Ashamalla S, et al. Association of transanal total mesorectal excision with local recurrence of rectal cancer. JAMA Netw Open. 2021;4(2): e2036330.

PubMed  PubMed Central  Google Scholar 

Matsuda T, Sawada R, Hasegawa H, Yamashita K, Harada H, Urakawa N, et al. Learning curve for transanal total mesorectal excision for low rectal malignancy. J Am Coll Surg. 2023;236(5):1054–63.

PubMed  Google Scholar 

Roodbeen SX, Spinelli A, Bemelman WA, Di Candido F, Cardepont M, Denost Q, et al. Local recurrence after transanal total mesorectal excision for rectal cancer: a multicenter cohort study. Ann Surg. 2021;274(2):359–66.

PubMed  Google Scholar 

Shin JK, Kim HC, Yun SH, Park YA, Cho YB, Huh JW, et al. Comparison oftransanal total mesorectal excision and robotic total mesorectal excision forlow rectal cancer after neoadjuvant chemoradiotherapy. Surg Endosc. 2021;35(12):6998–7004.

PubMed  Google Scholar 

Alhanafy MK, Park SS, Park SC, Park B, Kim MJ, Sohn DK, et al. Early experience with transanal total mesorectal excision compared with laparoscopic total mesorectal excision for rectal cancer: a propensity score-matched analysis. Dis Colon Rectum. 2020;63(11):1500–10.

PubMed  Google Scholar 

Weiser MR. AJCC 8th edition: colorectal cancer. Ann Surg Oncol. 2018;25(6):1454–5.

PubMed  Google Scholar 

Shimada A, Matsuda T, Sawada R, Hasegawa H, Yamashita K, Harada H, et al. The modified Glasgow prognostic score is a reliable predictor of oncological outcomes in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy. Sci Rep. 2023;13(1):17111.

CAS  PubMed  PubMed Central  Google Scholar 

Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42.

PubMed  Google Scholar 

Matsuda T, Yamashita K, Hasegawa H, Arimoto A, Watanabe A, Yamamoto M, et al. Reliable dissection technique during transanal total mesorectal excision using a lateral-first approach. Dis Colon Rectum. 2020;63(6):859.

PubMed  Google Scholar 

Yi X, Zhang X, Li Q, Ouyang J. Comparing perioperative and oncological outcomes of transanal and laparoscopic total mesorectal excision for rectal cancer: a meta-analysis of randomized controlled trials and prospective studies. Surg Endosc. 2023;37(12):9228–43.

PubMed  Google Scholar 

Fujita S, Akasu T, Mizusawa J, Saito N, Kinugasa Y, Kanemitsu Y, Colorectal Cancer Study Group of Japan Clinical Oncology Group, et al. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol. 2012;13(6):616–21.

PubMed  Google Scholar 

Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol. 2016;34(27):3300–7.

CAS  PubMed  Google Scholar 

Li SF, Wei R, Yu GH, Jiang Z. Predictive value of indirect bilirubin before neoadjuvant chemoradiotherapy in evaluating prognosis of local advanced rectal cancer patients. World J Gastrointest Oncol. 2022;14(11):2224–37.

PubMed  PubMed Central  Google Scholar 

Liu H, Wei R, Li C, Zhao Z, Guan X, Yang M, et al. BMI may be a prognostic factor for local advanced rectal cancer patients treated with long-term neoadjuvant chemoradiotherapy. Cancer Manag Res. 2020;12:10321–32.

CAS  PubMed  PubMed Central  Google Scholar 

De Nardi P, Salandini M, Chiari D, Pecorelli N, Cristel G, Damascelli A, et al. Changes in body composition during neoadjuvant therapy can affect prognosis in rectal cancer patients: an exploratory study. Curr Probl Cancer. 2020;44(2): 100510.

PubMed  Google Scholar 

Horie K, Matsuda T, Yamashita K, Hasegawa H, Utsumi M, Urakawa N, et al. Sarcopenia assessed by skeletal muscle mass volume is a prognostic factor for oncological outcomes of rectal cancer patients undergoing neoadjuvant chemoradiotherapy followed by surgery. Eur J Surg Oncol. 2022;48(4):850–6.

PubMed  Google Scholar